Nuveen Asset Management LLC trimmed its holdings in shares of Genmab A/S (NASDAQ:GMAB) by 13.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 508,500 shares of the company’s stock after selling 80,256 shares during the quarter. Nuveen Asset Management LLC’s holdings in Genmab A/S were worth $20,676,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the stock. San Francisco Sentry Investment Group CA purchased a new position in Genmab A/S in the fourth quarter worth about $32,000. Veriti Management LLC purchased a new position in shares of Genmab A/S in the 4th quarter worth approximately $42,000. Penserra Capital Management LLC boosted its holdings in shares of Genmab A/S by 192.1% in the 4th quarter. Penserra Capital Management LLC now owns 1,075 shares of the company’s stock worth $43,000 after purchasing an additional 707 shares during the period. BNC Wealth Management LLC bought a new position in shares of Genmab A/S during the 3rd quarter valued at approximately $112,000. Finally, Ellevest Inc. raised its holdings in Genmab A/S by 98.1% during the 4th quarter. Ellevest Inc. now owns 2,997 shares of the company’s stock valued at $122,000 after buying an additional 1,484 shares during the period. 6.24% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have weighed in on GMAB shares. Truist boosted their price objective on shares of Genmab A/S from $42.00 to $47.00 in a research report on Thursday, February 25th. Barclays reiterated an “overweight” rating on shares of Genmab A/S in a report on Wednesday, February 24th. Morgan Stanley downgraded shares of Genmab A/S from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 19th. Zacks Investment Research cut Genmab A/S from a “hold” rating to a “sell” rating in a research note on Friday, February 26th. Finally, Royal Bank of Canada raised their price target on Genmab A/S from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, January 4th. Three analysts have rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $42.63.
Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Monday, February 22nd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.02. Genmab A/S had a return on equity of 34.40% and a net margin of 50.99%. On average, sell-side analysts expect that Genmab A/S will post 1.09 EPS for the current fiscal year.
Genmab A/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL.
Featured Article: What is a Fiduciary?
Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMAB).
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.